Emory University helped lead research on drug to treat COVID-19 patients
On Apr. 29, 2020, Emory University played a leading role in the government-sponsored clinical trial of the COVID-19…
BioAegis demonstrated Gelsolin therapy can quell the cytokine storm and promote tissue repair
On Apr. 27, 2020, BioAegis Therapeutics announced it had published gene expression data in animal studies where recombinant…
Celdara Medical entered into a CRADA with USAMRIID and the Geneva Foundation
On Apr. 17, 2020, Celdara Medical announced that it had entered into a Cooperative Research and Development Agreement…
Fujifilm accelerated production of its influenza antiviral drug ‘Avigan tablet’ for COVID-19
On Apr. 15, 2020, FUJIFILM announced that it had expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co.,…
Fujifilm announced the start of a phase II clinical trial of its influenza antiviral drug ‘Avigan’ Tablet for COVID-19 patients in the U.S.
On Apr. 9, 2020, FUJIFILM announced initiation of a U.S. phase II clinical trial to evaluate the safety…
USDA confirmed highly pathogenic H7N3 avian influenza in a commercial flock in Chesterfield County, South Carolina
On Apr. 9, 2020, the U.S. Department of Agriculture (USDA) confirmed the presence of highly pathogenic H7N3 avian…
Nanomix awarded BARDA contract for development of rapid, mobile, point-of-care assays to detect COVID-19
On Apr. 8, 2020, Nanomix announced that the company had been awarded $570,000 in funding from Biomedical Advanced…
FDA approved Emory University human clinical trials for Emory COVID-19 antiviral
On Apr. 7, 2020, the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug application by…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Life Science News | Non-Profit Research | Therapeutics
Mesa Biotech to develop molecular point-of-care diagnostic test for novel Coronavirus (COVID-19)
On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza…
UW-Madison, FluGen and Bharat Biotech announced development of CoroFlu, a coronavirus vaccine
On Apr. 2, 2020, an international collaboration of virologists at the University of Wisconsin-Madison and the vaccine companies…
Fujifilm announced start of phase III clinical trial of influenza antiviral drug ‘Avigan Tablet’ on COVID-19 patients
On Mar. 31, 2020, FUJIFILM announced initiation of a phase III clinical trial to evaluate the safety and…
Cue Health awarded $13 million for rapid, portable, point-of-Care COVID-19 test by BARDA
On Mar. 31, 2020, Cue Health announced that is had been awarded up to $30 million in base…
Emergent BioSolutions signed agreement with Novavax to manufacture NanoFlu
On Mar. 31, 2020, Emergent BioSolutions announced an agreement with Novavax whereby Emergent provided molecule-to-market contract development and…
Biotechnology | COVID-19 | Influenza | Life Science News | Non-Profit Research | Therapeutics | Vaccine
Amyris launched hand sanitizer and receives initial positive result for vaccine adjuvant
On Mar. 26, 2020, Amyris announced that it had completed initial testing of a leading vaccine adjuvant. In…
Novavax NanoFlu achieved all primary endpoints in phase 3 clinical trial
On Mar. 24, 2020, Novavax announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu,…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Life Science News | Therapeutics | Vaccine
serum therapy used as possible COVID-19 treatment
On Mar. 23, 2020, researchers at Washington University School of Medicine in St. Louis announced they were investigating…
New study expanded understanding of influenza-associated complications
On Mar. 20, 2020, a study was published in JAMA that expands the understanding of influenza-associated complications. Influenza…
Mesa Biotech received funding from HHS for development of a 30 minute molecular point-of-care SARS-CoV-2 test
On Mar. 19, 2020, Mesa Biotech announced it had been awarded a $561,000 contract from the U.S. Department…
FDA approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for adults 65 years and older
On Feb. 24, 2020, Seqirus announced that the U.S. Food and Drug Administration (FDA) had approved the first…
BioAegis announced publication: ‘Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza’
On Dec. 12, 2019, BioAegis Therapeutics announced publication of new research findings with recombinant human plasma gelsolin in…
Researchers at Vanderbilt University Medical Center isolated an antibody that blocks bird flu
On Dec. 12, 2019, Vanderbilt University Medical Center (VUMC) researchers James Crowe Jr., MD, and colleagues announced they…
Seqirus’ Received Health Canada approval of first cell-based seasonal influenza vaccine
On Dec. 11, 2019, Seqirus announced that its cell-based quadrivalent influenza vaccine (QIVc) had received approval from Health…
FDA approved Fluzone High-Dose Quadrivalent for adults 65+ years of age for 2020-21 flu season
On Nov. 4, 2019, the U.S. Food and Drug Administration (FDA) approved Fluzone High-Dose Quadrivalent (Sanofi Pasteur) for…
Genentech announced FDA approval of antiviral drug Xofluza (Baloxavir Marboxil)
On Oct. 17, 2019, Genentech announced the U.S. Food and Drug Administration (FDA) had approved Xofluza (Baloxavir Marboxil),…
The NIH awarded up to $130 million over seven years for UGA to develop universal flu vaccine
On Sept. 30, 2019, the University of Georgia (UGA) announced it had signed a contract with the National…
Biotechnology | CDC | Infectious Disease | Influenza | Life Science News | Non-Profit Research | Vaccine
CDC released ACIP recommendations on use of influenza vaccines for the 2019-20 influenza season
On Aug. 23, 2019, the Centers for Disease Control and Prevention (CDC) released Immunization Practices Advisory Committee (ACIP)…
DARPA funded a $21.9 gene modulation research initiative at Georgia Tech, targeting influenza pandemics
In Jun. 2019, Defense Advanced Research Projects Agency (DARPA) announced it had funded a $21.9 gene modulation research…
Vaccitech universal flu vaccine passed Phase 2b clinical development milestones
On Jun. 5, 2019, Vaccitech announced that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100)…
FDA approved use of the 05 mL dose of Sanofi’s Fluzone Quadrivalent influenza vaccine to include children age 6 through 35 months
On Jan. 23, 2019, U.S. Food and Drug Administration (FDA) announced it had approved approved the use of…
Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season
On Dec. 5, 2018, Seqirus, a CSL subsidiary, announced real-world data showing that its cell-based quadrivalent influenza vaccine…